Louise Rodino-Klapac - Aug 5, 2025 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role: President, R&D and Tech Ops
Signature: /s/ Cristin Rothfuss, as Attorney-in-Fact for Louise Rodino-Klapac
Stock symbol: SRPT
Transactions as of: Aug 5, 2025
Transactions value $: $0
Form type: 4
Date filed: 8/6/2025, 08:01 PM
Previous filing: Mar 11, 2025
Next filing: Sep 5, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Rodino-Klapac Louise	President, R&D and Tech Ops	215 FIRST STREET, SUITE 415, CAMBRIDGE	/s/ Cristin Rothfuss, as Attorney-in-Fact for Louise Rodino-Klapac	2025-08-06	0001836218

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SRPT	Performance Stock Units	Award	$0	+6.25K		$0.00	6.25K	Aug 5, 2025	Common Stock	6.25K		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

Content

Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.